GATINEAU, QC--(Marketwired - August 15, 2017) - The Hydropothecary Corporation (TSX VENTURE: THCX) (the "Company" or "Hydropothecary") is pleased to announce it has started shipping Honeydew, the Company's highest CBD:THC ratio product offering to date.

Part of the Company's mid-market H2 product line, the dried bud has a ratio of 18.5 percent CBD to 1.8 percent THC, making it one of the highest CBD products available under Health Canada's regulations.

Honeydew complements the Company's existing CBD offerings, and brings the Company's total number of CBD products to five, including the recently released Passion Fruit. Passion Fruit is an indica-dominant hybrid cannabis strain that offers a 1:2 ratio of 5.1 percent THC to 10.7 percent CBD. Rounding out the CBD offering is Midday, Decarb 1:1 and Decarb High CBD.

"Together with our other H2 products, including Passion Fruit, Papaya Grove, Dragon Fruit, Bitter Melon and Juniper Berry, Honeydew has been developed to meet the needs of our clients at affordable prices, starting at just $7.25/g. Every new product we roll out has been carefully developed in response to what health care professionals need to help their patients," says Sebastien St-Louis, CEO and co-founder.

Honeydew and Passion Fruit are both available for $10/g under the H2 product line. For more information, please visit

About The Hydropothecary Corporation

Hydropothecary is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary's branding, cannabis product offering, patient service standards and product pricing are consistent with Hydropothecary's positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Image Available:

Contact Information:

For further information, please contact:

Jennifer Smith
Manager of Financial Reporting and Investor Relations
1-866-438-THCX (8429)